Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302% below fair value
$31.59−0.17 (-0.54%)
Close on Nov 13, 2026Market cap $1.89BP/E –Yield –
Agios Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Agios Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 93.8%. For fiscal 2025 it was 88.3%, against 88.6% the year before. The highest annual figure on record is 100.0% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.3% | −0.3 |
| FY2024 | Dec 31, 2024 | 88.6% | −0.7 |
| FY2023 | Dec 31, 2023 | 89.3% | +1.2 |
| FY2022 | Dec 31, 2022 | 88.0% | −10.8 |
| FY2019 | Dec 31, 2019 | 98.9% | +0.4 |
| FY2018 | Dec 31, 2018 | 98.5% | −1.5 |
| FY2017 | Dec 31, 2017 | 100.0% | +0.0 |
| FY2016 | Dec 31, 2016 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 95.4% | +8.5 |
| Q2 FY2026 | Jun 30, 2026 | 93.3% | +7.0 |
| Q1 FY2026 | Mar 31, 2026 | 93.6% | +6.1 |
| Q4 FY2025 | Dec 31, 2025 | 90.6% | +2.3 |
| Q3 FY2025 | Sep 30, 2025 | 87.0% | −4.3 |
| Q2 FY2025 | Jun 30, 2025 | 86.3% | +3.7 |
| Q1 FY2025 | Mar 31, 2025 | 87.6% | −4.8 |
| Q4 FY2024 | Dec 31, 2024 | 88.3% | −3.5 |
| Q3 FY2024 | Sep 30, 2024 | 91.3% | −0.2 |
| Q2 FY2024 | Jun 30, 2024 | 82.6% | −0.8 |
| Q1 FY2024 | Mar 31, 2024 | 92.3% | +2.2 |
| Q4 FY2023 | Dec 31, 2023 | 91.7% | +1.3 |
| Q3 FY2023 | Sep 30, 2023 | 91.4% | +6.1 |
| Q2 FY2023 | Jun 30, 2023 | 83.5% | −8.7 |
| Q1 FY2023 | Mar 31, 2023 | 90.1% | +30.9 |
| Q4 FY2022 | Dec 31, 2022 | 90.4% | −7.4 |
| Q3 FY2022 | Sep 30, 2022 | 85.3% | −12.9 |
| Q2 FY2022 | Jun 30, 2022 | 92.2% | −6.0 |
| Q1 FY2022 | Mar 31, 2022 | 59.3% | −40.1 |
| Q4 FY2020 | Dec 31, 2020 | 97.8% | −1.4 |
| Q3 FY2020 | Sep 30, 2020 | 98.2% | −0.3 |
| Q2 FY2020 | Jun 30, 2020 | 98.2% | −0.7 |
| Q1 FY2020 | Mar 31, 2020 | 99.4% | +0.5 |
| Q4 FY2019 | Dec 31, 2019 | 99.2% | +1.5 |
| Q3 FY2019 | Sep 30, 2019 | 98.5% | +3.1 |
| Q2 FY2019 | Jun 30, 2019 | 98.8% | −1.2 |
| Q1 FY2019 | Mar 31, 2019 | 98.9% | −1.1 |
| Q4 FY2018 | Dec 31, 2018 | 97.7% | −2.3 |
| Q3 FY2018 | Sep 30, 2018 | 95.4% | −4.6 |
| Q2 FY2018 | Jun 30, 2018 | 100.0% | – |
| Q1 FY2018 | Mar 31, 2018 | 100.0% | – |
| Q4 FY2017 | Dec 31, 2017 | 100.0% | – |
| Q3 FY2017 | Sep 30, 2017 | 100.0% | – |
See a number that looks wrong?